Desideriu Laky

Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors

Eyal Mishani, Galith Abourbeh, Yulia Rozen et al. · Nuclear Medicine and Biology · 2004 · 69 citations

Oncologic Imaging, Medicine, Potential Pet Bioprobes +7

Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer

Mazal Shaul, Galith Abourbeh, Orit Jacobson et al. · Bioorganic & Medicinal Chemistry · 2004 · 61 citations

Engineering, Oncologic Imaging, Novel Iodine-124 +10

The effect of the [F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety—An EGFR putative irreversible inhibitor

Samar Dissoki, Yoel Aviv, Desideriu Laky et al. · Applied Radiation and Isotopes · 2007 · 31 citations

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +8

Fluorine‐18 labeling of ML04 – presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer

Samar Dissoki, Desideriu Laky, Eyal Mishani · Journal of Labelled Compounds and Radiopharmaceuticals · 2006 · 19 citations

Chiral dimethylamine flutamide derivatives—modeling, synthesis, androgen receptor affinities and carbon-11 labeling

Orit Jacobson, Desideriu Laky, Kathryn E. Carlson et al. · Nuclear Medicine and Biology · 2006 · 16 citations

Molecular Pharmacology, Medicinal Chemistry, Derivative (Chemistry) +12